RAS mutations (including those in HRAS, NRAS and KRAS) occur in approximately 25% of cases of fusion-negative (embryonal) rhabdomyosarcoma (RMS) and may occur at a higher frequency in younger patients [39, 40]. This evidence concerns the gene HRAS and rhabdomyosarcoma.